Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
暂无分享,去创建一个
[1] M. Hattori,et al. Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome , 2022, Pediatric Nephrology.
[2] B. Rovin,et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.
[3] J. Thurman,et al. A clinical approach to children with C3 glomerulopathy , 2021, Pediatric Nephrology.
[4] T. Cavero,et al. Update on C3 Glomerulopathy: A Complement-Mediated Disease , 2020, Nephron.
[5] L. Greenbaum,et al. Nephrotic Syndrome. , 2019, Pediatric clinics of North America.
[6] G. Remuzzi,et al. C3 glomerulopathy — understanding a rare complement-driven renal disease , 2019, Nature Reviews Nephrology.
[7] S. Agrawal,et al. Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome , 2016, Scientific Reports.
[8] R. Fukuzawa,et al. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: Frequency, clinical features, and outcome in children , 2015, Nephrology.
[9] P. Sarafidis,et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] B. Ranchin,et al. Disease recurrence in paediatric renal transplantation , 2009, Pediatric Nephrology.
[11] P. Kincaid‐smith,et al. Reduction of proteinuria by rosiglitazone in non‐diabetic renal disease , 2007, Nephrology.
[12] A. Pozzi,et al. PPAR-γ agonist protects podocytes from injury , 2007 .